|2.||Neoplasm Metastasis (Metastasis)
|3.||Lung Neoplasms (Lung Cancer)
|5.||Breast Neoplasms (Breast Cancer)
|1.||Rosell, Rafael: 132 articles (06/2015 - 02/2002)|
|2.||Shepherd, Frances A: 115 articles (12/2015 - 03/2002)|
|3.||Zhang, Li: 115 articles (09/2015 - 10/2003)|
|4.||Gridelli, Cesare: 113 articles (09/2015 - 04/2002)|
|5.||Nakagawa, Kazuhiko: 111 articles (01/2016 - 01/2002)|
|6.||Fukuoka, Masahiro: 90 articles (12/2014 - 01/2002)|
|7.||Komaki, Ritsuko: 89 articles (06/2015 - 04/2002)|
|8.||Kiura, Katsuyuki: 88 articles (09/2015 - 03/2002)|
|9.||Herbst, Roy S: 87 articles (01/2015 - 01/2002)|
|10.||Park, Keunchil: 86 articles (01/2016 - 01/2002)|
|1.||Cisplatin (Platino)FDA LinkGeneric
10/01/1997 - "A hyperfractionated radiation therapy (HFX RT) trial (1.2 Gy twice daily, b.i.d.) (HFX) for non-small cell lung cancer (NSCLC) showed that 69.6 Gy resulted in better survival than did lower total doses (Radiation Therapy Oncology Group, RTOG 83-11) and that cisplatin concurrent with irradiation improved local control and survival over RT alone (Radiation Therapy Oncology Group, RTOG 91-06). "
03/01/2002 - "Since the 1980s, cisplatin therapy for advanced non-small-cell lung cancer (NSCLC) has shown improvement in patient outcome with respect to overall survival. "
12/01/2009 - "Cisplatin is widely used for the treatment of non-small-cell lung cancer. "
01/01/1987 - "[Therapeutic efficacy and pharmacokinetics of cisplatin in patients with non-small cell lung cancer]."
01/01/2013 - "Protective effects of ADAM8 against cisplatin-mediated apoptosis in non-small-cell lung cancer."
|2.||Epidermal Growth Factor Receptor (EGF Receptor)IBA
08/11/2015 - "Targeting these driver mutations, such as sensitizing epidermal growth factor receptor (EGFR) mutations, has dramatically improved the prognosis of advanced non-small cell lung cancer (NSCLC). "
03/01/2012 - "Applying a previously developed non-small cell lung cancer model, we assess 'cross-scale' the therapeutic efficacy of targeting a variety of molecular components of the epidermal growth factor receptor (EGFR) signalling pathway. "
11/01/2010 - "Therapeutic agents directed against the epidermal growth factor receptor (EGFR) signaling pathway have been effective in the treatment of non-small cell lung cancer (NSCLC). "
04/01/2009 - "Epidermal growth factor receptor (EGFR) inhibitors are effective in a subset of patients with non-small-cell lung cancer (NSCLC). "
09/01/2010 - "The emerging role of epidermal growth factor receptor (EGFR) inhibitors in first-line treatment for patients with advanced non-small cell lung cancer positive for EGFR mutations."
|3.||Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
08/01/2009 - "The EGFR has been targeted through the development of selective tyrosine kinase inhibitors (TKIs) that have proven effective in a subset of non-small cell lung cancer (NSCLC) patients, many bearing gain-of-function EGFR mutations or egfr gene amplification. "
01/01/2014 - "This type of non-small-cell lung carcinoma more frequently involves EGFR gene abnormalities, which determine the efficacy of EGFR tyrosine kinase inhibitor therapies (EGFR TKIs). "
01/01/2015 - "Tyrosine kinase inhibitors (TKIs) against EGFR and c-Met are initially effective when administered individually or in combination to non-small cell lung cancer (NSCLC) patients. "
04/01/2014 - "[Association between GNAS1 T393C polymorphism and therapeutic efficacy of tyrosine kinase inhibitor in pretreated advanced non-small cell lung cancer with unknown EGFR mutation status]."
01/01/2015 - "EGFR tyrosine-kinase inhibitors (TKIs) have now been firmly established as the first-line treatment for non-small-cell lung cancer (NSCLC) patients harboring activating EGFR mutations, based on seven prospective randomized Phase III trials. "
|4.||gefitinib (Iressa)FDA Link
02/24/2005 - "Here we report the case of a patient with EGFR-mutant, gefitinib-responsive, advanced non-small-cell lung cancer who had a relapse after two years of complete remission during treatment with gefitinib. "
10/01/2004 - "(8) In practice, more thorough assessment of gefitinib is needed to determine whether this new drug is beneficial for patients with non small-cell lung cancer. "
08/01/2004 - "There have been several reports of good response to gefitinib therapy at the first time in patients with advanced non-small cell lung cancer, but few reports of recurrence in patients after successful therapy with this agent. "
11/01/2008 - "Gefitinib has been reported to be more effective in patients with non-small-cell lung cancer (NSCLC) who had low or never-smoking history than for heavier smokers. "
07/11/2005 - "Gefitinib is more effective in never-smokers with non-small-cell lung cancer: experience among Asian patients."
12/05/2005 - "Although gemcitabine is a potent therapeutic agent in the treatment of human non-small cell lung cancer (NSCLC), resistance to gemcitabine is common. "
07/01/1999 - "Following the diagnosis of non-small cell lung carcinoma and subsequent treatment with gemcitabine (a second-line chemotherapeutic agent), a significant reduction in both tumour mass and mucosal blistering was observed. "
03/01/2013 - "When less is better: the safety and efficacy of reduced intensity gemcitabine in a difficult patient population with advanced non-small-cell lung cancer."
05/01/1996 - "As the efficacy of gemcitabine in non-small cell lung cancer was equivalent when using both regimens, the better tolerated and more easily administered once-weekly schedule is recommended."
05/01/2010 - "The combination of gemcitabine and S-1 was determined to be feasible and effective for advanced non-small cell lung cancer. "
|6.||Paclitaxel (Taxol)FDA LinkGeneric
07/01/2004 - "We believe that using paclitaxel in concurrent chemoradiotherapy regimens may be effective in patients with unresectable, locoregionally advanced non-small cell lung cancer."
12/01/2001 - "Paclitaxel administered as a weekly 1-h infusion at a dose of 90 mg/m(2) is a safe and effective therapy for elderly patients with advanced non-small cell lung cancer. "
02/15/2013 - "On the other hand, paclitaxel (Taxol) is a new antineoplastic drug that has shown promise in the treatment of non-small cell lung cancer (NSCLC). "
04/01/1999 - "Several studies have been conducted to assess the safety and efficacy of paclitaxel plus radiation therapy in patients with non-small cell lung cancer (NSCLC) and to assess whether the radiosensitization demonstrated by paclitaxel in vivo can translate into clinical benefit. "
08/01/1997 - "A phase I study was conducted to investigate the safety and efficacy of twice-weekly paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) and concurrent thoracic irradiation in patients with stage III non-small cell lung cancer. "
|7.||Carboplatin (JM8)FDA LinkGeneric
03/01/2011 - "In this trial, the combination of Genexol® and carboplatin showed significant activity as first line treatment for patients with advanced or metastatic non-small cell lung cancer. "
11/01/2015 - "Although carboplatin is one of the standard chemotherapeutic agents for non-small cell lung cancer (NSCLC), it has limited therapeutic efficacy due to activation of a survival signaling pathway and the induction of multidrug resistance. "
09/01/1999 - "We conclude that for a moderate carboplatin dose in non-small cell lung cancer, the therapeutic index could be improved if dosage is calculated according to the AUC."
01/01/2012 - "Carboplatin has efficacy in treating advanced non-small cell lung cancer (NSCLC) in combination with other drugs. "
03/01/2013 - "Mistletoe as complementary treatment in patients with advanced non-small-cell lung cancer treated with carboplatin-based combinations: a randomised phase II study."
03/01/2010 - "Standard first-line therapy for non-small-cell lung cancer (NSCLC) with platinum-based agents, given in combination with cytotoxic compounds, has reached a relative plateau in its therapeutic efficacy. "
08/01/2007 - "Third-generation platinum-based combinations are established as first-line treatment for advanced non-small cell lung cancer (NSCLC). "
10/01/2007 - "The aim of this study was to determine the impact of patient selection based on age, comorbidity and performance status on the efficacy of platinum-free combination therapy on non-small-cell lung cancer after 65 years of age. "
11/01/2013 - "Platinum doublets as first-line treatment for elderly patients with advanced non-small cell lung cancer."
02/01/2012 - "Platinum-based regimens represent the standard first-line treatment for non-small-cell lung cancer (nsclc). "
|9.||erlotinib (CP 358,774)FDA Link
11/01/2006 - "Developmental studies of either drug have failed to show synergistic effects when combined with cytotoxic drugs as the first line treatment in patients with advanced non-small cell lung cancer, but erlotinib has shown survival prolongation when compared with best supportive care in patients with recurrence. "
06/01/2012 - "However, two recent clinical case reports showed that erlotinib caused complete remission of acute myeloid leukaemia (AML)-M1 in patients who had both AML-M1 and non-small-cell lung cancer. "
09/01/2013 - "A randomized trial carried out by Shepherd et al. in patients with advanced or metastatic non-small-cell lung cancer showed statistically significant benefit of erlotinib over placebo in prolonging overall survival and progression-free survival. "
11/01/2014 - "Findings from a phase 2 study in non-small cell lung cancer showed favourable efficacy for dacomitinib compared with erlotinib. "
03/01/2012 - "The purpose of this study was to evaluate the efficacy of erlotinib as front-line treatment in clinically selected patients with non-small-cell lung cancer (NSCLC). "
|10.||docetaxel (Taxotere)FDA Link
10/01/1999 - "Results of a multicenter phase III trial of docetaxel versus best supportive care for the first-line treatment of non-small cell lung cancer are pending. "
01/01/2003 - "The cytotoxic agent docetaxel not only has proven activity in non-small cell lung cancer-when used alone or in combination-but is also a potent radiosensitizer, and improved treatments are needed in all stages of this disease. "
01/01/2003 - "Docetaxel (Taxotere) is a potent anticancer agent, with proven efficacy as first-line therapy in non-small-cell lung cancer (NSCLC). "
06/01/1999 - "In the first-line treatment of advanced non-small cell lung cancer (NSCLC), phase II trials of single-agent docetaxel (Taxotere; Rhône-Poulenc Rorer, Antony, France) at a dose of 100 mg/m2 every 3 weeks have reported encouraging results, with an overall response rate of 29% and a median survival duration of 9 months. "
10/01/2007 - "According to this meta-analysis, docetaxel is superior to vinca alkaloid-based regimens in terms of OS and safety for first-line therapy of advanced non-small cell lung cancer."
|1.||Drug Therapy (Chemotherapy)
01/01/2009 - "After several years of clinical trials in the setting of advanced non-small-cell lung cancer (NSCLC) that were characterized by a lack of efficacy of chemotherapy over best supportive care, we have more recently seen meaningful clinical benefits realized from selected targeted therapies. "
05/01/2012 - "Chemotherapy remains the first-line treatment for most patients with stage IV non-small cell lung cancer (NSCLC), but optimal regimens are now defined by histology. "
02/20/2008 - "There is a temporal disease-free period after 1st line chemotherapy in advanced non-small cell lung cancer (NSCLC), most of patients need 2nd line chemotherapy. "
09/01/2006 - "Chemotherapy (CT) is recommended in numerous clinical guidelines for advanced non-small cell lung cancer (NSCLC) and offers improved survival over best supportive care. "
07/01/2005 - "Chemotherapy prolongs the survival of patients with advanced non-small cell lung cancer compared with best supportive care alone by 3 to 6 months, with the newer generation of agents producing slightly better survival statistics and some improvement in quality of life. "
04/01/2015 - "Stereotactic ablative radiotherapy (SABR) is a highly effective treatment for early-stage non-small cell lung cancer. "
07/01/2001 - "Radical radiotherapy, the mainstay of treatment for early inoperable non-small-cell lung cancer, is most commonly given in daily fractions, Monday to Friday, to a total dose of 60-70 Gy over 6-8 weeks. "
10/01/2015 - "Conventionally fractionated radiotherapy (CFRT) has proven ineffective in treating non-small cell lung cancer while more promising results have been obtained with stereotactic body radiotherapy (SBRT). "
10/01/2006 - "Patient-assessed health-related quality-of-life (HRQOL) scores, together with demographic and clinical factors in stage III non-small cell lung cancer (NSCLC) patients, are important prognostic factors for survival and may be helpful in determining thoracic radiotherapy (TRT) strategy. "
06/01/2006 - "To evaluate the efficacy of curative and palliative radiotherapy in inoperable advanced non-small cell lung cancer (NSCLC) patients with a performance status (PS) equal or greater than 2, and to compare the therapy effect on survival with or without metastatic disease. "
01/01/2007 - "Adjuvant chemotherapy has been proven to be beneficial for patients with early stage non-small cell lung cancer. "
10/20/2006 - "Recently, results from IALT, JBR10 and CALGB9633 showed that postoperative adjuvant chemotherapy improved survival rate of patients with non-small cell lung cancer (NSCLC) after complete resection. "
04/01/2013 - "Adjuvant chemotherapy is beneficial in non-small-cell lung cancer (NSCLC). "
05/10/2007 - "The beneficial results achieved with adjuvant chemotherapy in the general population with early non-small-cell lung cancer (NSCLC) cannot be automatically extrapolated to the elderly, who are at higher risk of toxicity. "
07/01/2005 - "The therapeutic efficacy of adjuvant chemotherapy following surgical resection of early stage non-small cell lung cancer (NSCLC) has been less clear. "
|4.||Combination Drug Therapy (Combination Chemotherapy)
01/01/2003 - "Combination chemotherapy has been shown to improve overall survival compared with best supportive care in patients with advanced non-small cell lung cancer (NSCLC). "
04/01/1995 - "Although quite small, this increase in survival, coupled with a certain improved 'quality of life' suggests that polychemotherapy should be recommended for patients with non-resectable non-small cell lung cancer."
07/03/1993 - "Although small, this increase in survival, together with an improved quality of life, suggests that polychemotherapy should be recommended for patients with non-resectable non small cell lung cancer."
12/01/1984 - "This four-drug combination chemotherapy is concluded to be effective for non-small cell lung cancer."
05/01/1990 - "These results indicate that this combination chemotherapy is safe and effective for non-small cell lung cancer in the elderly patients and patients with reduced renal function and warrants further clinical trials."
|5.||Heterologous Transplantation (Xenotransplantation)
11/01/2010 - "The efficacy of combined treatment with 8.3 mg/kg S-1 and 2 Gy X-ray irradiation in treating non-small cell lung cancer xenografts (Lu-99 and LC-11) was significantly higher than that of treatment with S-1 alone or 2 Gy X-ray irradiation alone, and the antitumor activity of combined treatment was similar to that of 5 Gy X-ray irradiation alone. "
08/15/2007 - "The preclinical safety and efficacy of AND-p53sm were studied in healthy mice and mice bearing orthotopic human non-small-cell lung cancer (NSCLC) xenograft. "
08/01/2015 - "The first study examined the effect of 5 and 10 mg/kg peloruside (QD×5) on the growth of H460 non-small cell lung cancer xenografts. "
04/01/2014 - "For biodistribution studies (96 h after injection of tracer) 10 μg of (89)Zr-PRS-110 (with 0-490 μg of unlabeled PRS-110) were injected into BALB/c mice bearing high MET-expressing H441 non-small cell lung cancer xenografts. "
04/01/2013 - "In vivo efficacy studies using a non-small cell lung carcinoma xenograft revealed that CS-PEG-anti-TMEFF-2 NCs resulted as effective as free DCX (Taxotere®). "